menu toggle
Thursday, November 26 - Friday, November 27
Cencora will be closed on Thursday, November 26 in observance of the Thanksgiving holiday. There will be no deliveries on this day and our Customer Service and Customer Systems Support teams will be unavailable. Our offices will also be closed on Friday, November 27. While deliveries for non-refrigerated product will be attempted on Friday, our offices will be closed. Customer Service may be limited and Customer System Support will also be limited and available by email only. Please review our full holiday schedule for more detailed information and to plan your orders accordingly.

September 21, 2021

FDA approves first biosimilar to treat macular degeneration disease and other eye conditions

On September 17, The U.S. Food and Drug Administration approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older. Byooviz is also approved to treat macular edema (fluid build-up) following retinal vein occlusion (blockage of veins in the retina) and myopic choroidal neovascularization, a vision-threatening complication of myopia (nearsightedness).